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Introduction {#jdv15570-sec-0006}
============

Anogenital warts (AGW) are epidermal growth lesions, caused by the different genotypes of human papillomavirus (HPV), which occur in the anogenital areas of males and females.[1](#jdv15570-bib-0001){ref-type="ref"}, [2](#jdv15570-bib-0002){ref-type="ref"} More than 90% of cases of AGW are caused by HPV types 6 and 11.[3](#jdv15570-bib-0003){ref-type="ref"}, [4](#jdv15570-bib-0004){ref-type="ref"} Usually, HPV is contracted via sexual interactions, while other potential routes of viral transmission are rare.[5](#jdv15570-bib-0005){ref-type="ref"} AGW represent a failure of immune recognition, although they only rarely have oncogenic potential and are not linked to cervical cancer.[6](#jdv15570-bib-0006){ref-type="ref"} Although the transmission of HPV does not necessitate clinical lesions to be present, the viral burden of AGW is usually high and can therefore facilitate transmission.

Anogenital warts are a cosmetic nuisance and may cause substantial psychosocial issues for patients,[6](#jdv15570-bib-0006){ref-type="ref"} as well as creating an economic burden on healthcare systems. The emotional and psychological issues associated with a diagnosis of AGW can include shame, embarrassment, anger, depression and guilt.[4](#jdv15570-bib-0004){ref-type="ref"}, [7](#jdv15570-bib-0007){ref-type="ref"}, [8](#jdv15570-bib-0008){ref-type="ref"} Warts and the majority of the treatment modalities for the condition may also cause physical problems such as pain, itching, burning, irritation, and very rarely, obstruction during childbirth.[2](#jdv15570-bib-0002){ref-type="ref"}, [3](#jdv15570-bib-0003){ref-type="ref"} In addition, AGW can impact the sexual activity of patients, either through fear of transmission or embarrassment of lesions.[9](#jdv15570-bib-0009){ref-type="ref"} Furthermore, AGW are associated with substantial direct and indirect costs.[10](#jdv15570-bib-0010){ref-type="ref"} A recent study estimated that the direct cost of genital wart management in the United Kingdom (UK) in 2012 was £58.44 million.[11](#jdv15570-bib-0011){ref-type="ref"} The main drivers of cost were disease recurrence, the requirement for repeat physician visits and treatment.

The aim of this position statement is to provide guidance for physicians on the diagnosis and management of AGW in daily clinical practice. The guidance is intended to supplement, rather than replace, existing evidence‐based treatment guidelines.[12](#jdv15570-bib-0012){ref-type="ref"}, [13](#jdv15570-bib-0013){ref-type="ref"}, [14](#jdv15570-bib-0014){ref-type="ref"}

Methods {#jdv15570-sec-0007}
=======

An international panel of 14 global experts on AGW was convened to develop guidance on the diagnosis and management of AGW in an effort to unify international recommendations. Guidance was developed based on a review of published international and national guidelines on AGW.[12](#jdv15570-bib-0012){ref-type="ref"}, [13](#jdv15570-bib-0013){ref-type="ref"}, [14](#jdv15570-bib-0014){ref-type="ref"} A PubMed search was performed for articles published up to August 2016. Relevant literature on the diagnosis and management of AGW was evaluated. In situations where insufficient published information was available, recommendations were developed based on consensus of the authors' clinical experience. Professor O\'Mahony led communications via email to discuss the development of the position statement and created the initial draft of the manuscript. The remaining 13 experts reviewed the manuscript and provided their input and clinical expertise. The experts provided all images included in the position statement.

Guidance for the diagnosis of AGW {#jdv15570-sec-0008}
---------------------------------

In terms of diagnosis, the key challenge is ensuring that AGW are correctly identified. In the first instance, a diagnosis of AGW is usually made by the patient, which must then be confirmed by clinical inspection. In the case of uncertain lesions, polymerase chain reaction (PCR) diagnosis of different HPV genotypes can be attempted.

Typical presentations of AGW are shown in Fig. [1](#jdv15570-fig-0001){ref-type="fig"}. AGW appear as papillomatous plaques or flat lesions and can be single or multiple in number. Lesions vary from flesh‐coloured to white, pink or brown.[3](#jdv15570-bib-0003){ref-type="ref"} They typically manifest in areas of the body that are in close contact during sex: mainly on the anogenital areas such as vulva, penis, groin, perineum, perianal skin, but also in the oral cavity.[2](#jdv15570-bib-0002){ref-type="ref"} Diagnosis of clinically typical AGW does not require histological confirmation.

![Typical presentations of anogenital warts. (a) Acuminate genital warts: vulval warts, (b) Parafrenular papules with genital wart on frenulum: normal parafrenular papules together with warts on the frenulum, (c) Pigmented genital warts: widespread hyperkeratotic, confluent, pigmented papules of the anogenital region, (d) Leukoplakic genital warts: flat papules with a white surface over the foreskin; leucoplakia due to keratinization of mucosa, (e) Scattered penile genital warts: several lesions over foreskin and scrotum, (f) Multiple keratotic genital warts: multiple confluent papules of the vulva and perianal area, (g) Multiple non‐keratotic genital warts: typical localization of genital warts in men, (h) Multiple non‐keratotic genital warts: typical localization of anogenital warts in women.](JDV-33-1006-g001){#jdv15570-fig-0001}

There are many conditions that can be misinterpreted as AGW (Fig. [2](#jdv15570-fig-0002){ref-type="fig"}). Differential diagnoses that need to be excluded include normal skin variations (e.g. pearly penile papules, parafrenular glands, Fordyce spots, vestibular papillae, sebaceous cysts), other infectious or inflammatory conditions and other papules (syphilis on mucosal plates, molluscum contagiosum, lichen planus, psoriasis, condyloma lata) and benign or malignant neoplastic lesions (papillomatoses of vulva, nevi, verrucous carcinoma, invasive carcinoma, seborrhoeic keratosis, Bowen\'s disease, Buschke‐Löwenstein disease, pigmented or unpigmented grade 2--3 intraepithelial neoplasia, lymphangioma).[2](#jdv15570-bib-0002){ref-type="ref"}, [3](#jdv15570-bib-0003){ref-type="ref"} Pigmented or unusual lesions should be immediately referred to a specialist.

![Differential diagnoses (images on the left) of anogenital warts (images on the right). (a) (a1) Pearly penile papules: normal glands on the corona glandis, (a2) AGW: small cluster of warts on the coronal sulcus, (b) (b1) Parafrenular glands: normal glands on either side of frenulum, (b2) AGW: parafrenular glands with wart on the frenulum, (c) (c1) Fordyce spots: fordyce spots in a male, (c2) AGW: fordyce spots alongside a wart, (d) (d1) Papillomatoses of vulva: scattered raised glands can be confused with AGW, (d2) AGW: vulval warts -- scattered, soft and fleshy, the vestibular area, (e) (e1) Syphilis on mucosal plates: painless plaque, which suddenly appears on one or more mucosal membranes, (e2) AGW: penile wart, (f) (f1) Lichen planus: whitish, fine reticulate papules on the glans and corpus, (f2) AGW: white wart patch, (g) (g1) Molluscum contagiosum and (g2) AGW (arrows on image show lesions): both pink dome‐shaped papules and warts, (h) (h1) Bowen\'s disease: whitish plaque on labia minora, (h2) AGW: extensive genital warts, (i) (i1) Pigmented intraepithelial neoplasia: pigmented popular strips that extend to the anogenital area, (i2) AGW: penile pigmented warts, (j) (j1) Vulvar intraepithelial neoplasia: pigmented popular strips that extend to the anogenital area, (j2) AGW: extensive soft warts and one large keratinized wart, (k) (k1) Invasive carcinoma of the penis: invasive cancer of the glans of the penis arising from penile intraepithelial neoplasia, (k2) AGW: condylomata acuminata on the urethral mucosa, (l) (l1) Buschke‐Löwenstein: rapid expansion of budding masses that coalesce to form tumours, (l2) AGW: vulval and anal warts.](JDV-33-1006-g002){#jdv15570-fig-0002}

A checklist for the initial consultation with the patient is provided in Table [1](#jdv15570-tbl-0001){ref-type="table"}. This will help physicians when diagnosing AGW to get the relevant information from the patient in order to manage and treat the AGW effectively. A number of questions that physicians are frequently asked are shown in Table [2](#jdv15570-tbl-0002){ref-type="table"}, along with suggested answers. Patients should be reassured that if they have developed AGW, appropriate treatment can clear the warts within 3 months.[5](#jdv15570-bib-0005){ref-type="ref"} Patients should be informed that AGW are of mostly sexual origin and are caused by HPV which is contagious; therefore, it is important for patients to disclose their AGW to recent sexual partners, who should be advised to visit a physician if they have developed AGW. Physicians should also inform patients that smokers have a 27% increased risk of developing AGW compared with non‐smokers.[15](#jdv15570-bib-0015){ref-type="ref"} Furthermore, they should explain that HPV prevalence in patients who smoke is 48.2% compared with 37.5% for non‐smokers (*P* \< 0.001).[16](#jdv15570-bib-0016){ref-type="ref"} Generally, warts develop within weeks or months after acquiring HPV but in a significant number of cases, the virus can be dormant for months or years before warts emerge.[17](#jdv15570-bib-0017){ref-type="ref"}

###### 

Checklist for initial consultation

  Checklist
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Duration of genital wartsHistory of genital wartsLocation of other warts: anal and/or oralPrevious treatment(s) and clinical result(s)Patient with steady partner or with several partnersSmoking statusImmune suppression status and comorbiditiesDiabetesAllergy to anaestheticsHistory of other sexually transmitted infections

AGW, anogenital warts.

John Wiley & Sons, Ltd

###### 

Frequently asked questions and answers to guide discussion with patients

  Questions                                                     Answers
  ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***How did I get AGW?***                                      AGW are caused by HPV.[1](#jdv15570-bib-0001){ref-type="ref"} Usually, HPV is contracted via sexual interactions: indirect acquisition is rare[5](#jdv15570-bib-0005){ref-type="ref"}
  ***What is the risk of HPV transmission?***                   The risk of HPV transmission is very high (1.6 sexual interactions are enough to get the infection). The infection is very common and the vast majority of people have the virus during their lifetime
  ***Is there a treatment?***                                   Discuss the modalities and the limitations of treatment, explaining this will not eradicate the virus
  ***Does smoking increase my risk of developing AGW?***        Explain that smokers are at an increased risk of developing AGW and therefore, smoking cessation should be encouraged[15](#jdv15570-bib-0015){ref-type="ref"}
  ***How long will I have AGW for?***                           AGW can recur several times but with appropriate treatment, most warts should clear within 3 months[5](#jdv15570-bib-0005){ref-type="ref"}
  ***Is this the end of my sex life?***                         Reassure the patient that this is not the case
  ***Should I disclose to my current and previous partner?***   It is important to disclose you have AGW to your current partner in order to allow him/her to be checked
  ***Should I always use a condom?***                           Explain that data have shown that increased levels of condom use is associated with increased clearance of HPV.[88](#jdv15570-bib-0088){ref-type="ref"} It is therefore advisable to use condoms routinely
  ***What are the risks during pregnancy?***                    AGW can become large during pregnancy[5](#jdv15570-bib-0005){ref-type="ref"} but will usually disappear within weeks of delivery. In rare cases, HPV can be transmitted during child birth resulting in recurrent respiratory papillomatosis in the infant[73](#jdv15570-bib-0073){ref-type="ref"}, [78](#jdv15570-bib-0078){ref-type="ref"}
  ***Will I develop cancer?***                                  AGW are not related to cancer. AGW are caused by certain types of HPV, other types of HPV can cause cancer[5](#jdv15570-bib-0005){ref-type="ref"}
  ***Can AGW spread to other parts of the body?***              It is very uncommon for AGW to spread to other body locations

AGW, anogenital warts; HPV, human papillomavirus.

John Wiley & Sons, Ltd

Recommendations when selecting treatment options {#jdv15570-sec-0009}
------------------------------------------------

Treatment should be individualized for each patient. Although untreated warts can resolve spontaneously,[3](#jdv15570-bib-0003){ref-type="ref"}, [17](#jdv15570-bib-0017){ref-type="ref"} most patients want an immediate intervention to eradicate them. Treatments need to be selected on the basis of considerations such as the number, size, morphology, location and keratinization of warts, and whether they are new or recurrent.[8](#jdv15570-bib-0008){ref-type="ref"}, [18](#jdv15570-bib-0018){ref-type="ref"} Wart area should be taken into consideration as one study showed that AGW with smaller surface areas (2--19 mm^2^) require significantly fewer treatment episodes and take less time to clear than those with larger surface areas (100--1038 mm^2^).[19](#jdv15570-bib-0019){ref-type="ref"} Patient‐related considerations also need to be taken into account such as their preference for home or clinic‐based treatment, and the convenience of the regimen in terms of dosing frequency and duration.[8](#jdv15570-bib-0008){ref-type="ref"}, [18](#jdv15570-bib-0018){ref-type="ref"} Patient‐applied options are often preferred as they offer privacy, convenience and autonomy.[18](#jdv15570-bib-0018){ref-type="ref"}

Treatment options for AGW are provided in Table [3](#jdv15570-tbl-0003){ref-type="table"},[20](#jdv15570-bib-0020){ref-type="ref"}, [21](#jdv15570-bib-0021){ref-type="ref"}, [22](#jdv15570-bib-0022){ref-type="ref"}, [23](#jdv15570-bib-0023){ref-type="ref"}, [24](#jdv15570-bib-0024){ref-type="ref"}, [25](#jdv15570-bib-0025){ref-type="ref"}, [26](#jdv15570-bib-0026){ref-type="ref"}, [27](#jdv15570-bib-0027){ref-type="ref"}, [28](#jdv15570-bib-0028){ref-type="ref"}, [29](#jdv15570-bib-0029){ref-type="ref"}, [30](#jdv15570-bib-0030){ref-type="ref"}, [31](#jdv15570-bib-0031){ref-type="ref"}, [32](#jdv15570-bib-0032){ref-type="ref"}, [33](#jdv15570-bib-0033){ref-type="ref"}, [34](#jdv15570-bib-0034){ref-type="ref"}, [35](#jdv15570-bib-0035){ref-type="ref"}, [36](#jdv15570-bib-0036){ref-type="ref"}, [37](#jdv15570-bib-0037){ref-type="ref"}, [38](#jdv15570-bib-0038){ref-type="ref"}, [39](#jdv15570-bib-0039){ref-type="ref"}, [40](#jdv15570-bib-0040){ref-type="ref"}, [41](#jdv15570-bib-0041){ref-type="ref"}, [42](#jdv15570-bib-0042){ref-type="ref"}, [43](#jdv15570-bib-0043){ref-type="ref"}, [44](#jdv15570-bib-0044){ref-type="ref"}, [45](#jdv15570-bib-0045){ref-type="ref"}, [46](#jdv15570-bib-0046){ref-type="ref"}, [47](#jdv15570-bib-0047){ref-type="ref"}, [48](#jdv15570-bib-0048){ref-type="ref"}, [49](#jdv15570-bib-0049){ref-type="ref"}, [50](#jdv15570-bib-0050){ref-type="ref"}, [51](#jdv15570-bib-0051){ref-type="ref"}, [52](#jdv15570-bib-0052){ref-type="ref"}, [53](#jdv15570-bib-0053){ref-type="ref"}, [54](#jdv15570-bib-0054){ref-type="ref"}, [55](#jdv15570-bib-0055){ref-type="ref"}, [56](#jdv15570-bib-0056){ref-type="ref"}, [57](#jdv15570-bib-0057){ref-type="ref"}, [58](#jdv15570-bib-0058){ref-type="ref"}, [59](#jdv15570-bib-0059){ref-type="ref"}, [60](#jdv15570-bib-0060){ref-type="ref"}, [61](#jdv15570-bib-0061){ref-type="ref"}, [62](#jdv15570-bib-0062){ref-type="ref"}, [63](#jdv15570-bib-0063){ref-type="ref"}, [64](#jdv15570-bib-0064){ref-type="ref"} and individual modalities are discussed in more detail below. A recent meta‐analysis of 18 studies of patient‐applied therapies concluded that all are more effective than placebo, although treatments cannot be ranked in terms of efficacy due to a lack of head‐to‐head comparisons.[65](#jdv15570-bib-0065){ref-type="ref"}

###### 

Treatment options for AGW

  Treatment                                                 Mode of action                                                                                           Schedule                                                                                                          Clearance rate (%)   Recurrence rate (%)   Advantages                                                                                                                                                                                         Disadvantages                                                                                                                                                                      Refs
  --------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------- --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Ablative techniques**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Cryotherapy                                               Liquid nitrogen freezes and destroys lesions                                                             Applied directly to lesions; repeat for two or three cycles                                                       46--96               18--39                Rapid results in some patientsMinimal training                                                                                                                                                     High recurrence rateRepeat physician visitsPain, necrosis, hypopigmentation                                                                                                        [20](#jdv15570-bib-0020){ref-type="ref"}, [45](#jdv15570-bib-0045){ref-type="ref"}, [46](#jdv15570-bib-0046){ref-type="ref"}, [47](#jdv15570-bib-0047){ref-type="ref"}, [48](#jdv15570-bib-0048){ref-type="ref"}, [49](#jdv15570-bib-0049){ref-type="ref"}
  CO~2~ and Nd:YAG laser                                    Laser vaporizes lesions                                                                                  Under local anaesthesia, protocol depends on type of laser                                                        23--95               2.5--77               Rapid resultsEffective for thick lesions                                                                                                                                                           High recurrence rate; in some cases even before healing of laser treatmentRepeat physician visitsCostlySubstantial trainingExpertise requiredPain/scarringSmoke evacuator needed   [20](#jdv15570-bib-0020){ref-type="ref"}, [48](#jdv15570-bib-0048){ref-type="ref"}, [50](#jdv15570-bib-0050){ref-type="ref"}
  Electrocautery                                            High‐frequency electrical currents cause thermal damage to infected tissue                               Under local anaesthesia, base of lesion excised; repeat as required                                               35--94               20--25                Rapid results                                                                                                                                                                                      High recurrence rateRepeat physician visitsExpertise requiredSmoke evacuator needed                                                                                                [18](#jdv15570-bib-0018){ref-type="ref"}, [20](#jdv15570-bib-0020){ref-type="ref"}, [49](#jdv15570-bib-0049){ref-type="ref"}, [51](#jdv15570-bib-0051){ref-type="ref"}
  Surgery                                                   Scissor or scalpel excision                                                                              Under local or general anaesthesia; base of lesion excised                                                        89--93               18--65                Rapid resultsUseful for large lesions                                                                                                                                                              High recurrence ratePain/scarringExpertise required                                                                                                                                [52](#jdv15570-bib-0052){ref-type="ref"}, [53](#jdv15570-bib-0053){ref-type="ref"}, [54](#jdv15570-bib-0054){ref-type="ref"}
  Trichloroacetic acid (33--50%)                            Acid induces a chemical burn                                                                             One to three times per week; repeat as necessary                                                                  70--100              18--36                Rapid resultsSuitable for a few small lesions                                                                                                                                                      High recurrence rateRepeat physician visitsIntense burning sensation                                                                                                               [20](#jdv15570-bib-0020){ref-type="ref"}, [45](#jdv15570-bib-0045){ref-type="ref"}, [47](#jdv15570-bib-0047){ref-type="ref"}, [55](#jdv15570-bib-0055){ref-type="ref"}
  **Immunotherapies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Imiquimod 5%                                              Immunomodulator: stimulates interferon and cytokine production                                           Three nights per week for up to 16 weeks or longer                                                                35--75               6                     EfficacySimple regimenEasy self‐applicationPreferred by patientsLower recurrence rates than ablative techniquesInflammatory reactions extending beyond treatment area can show the infected area   Inflammatory reactions extending beyond treatment areaResponse may be slowLower clearance rates than ablative techniquesRare vitiligo‐like depigmentation                          [20](#jdv15570-bib-0020){ref-type="ref"}, [21](#jdv15570-bib-0021){ref-type="ref"}, [22](#jdv15570-bib-0022){ref-type="ref"}, [23](#jdv15570-bib-0023){ref-type="ref"}, [24](#jdv15570-bib-0024){ref-type="ref"}, [25](#jdv15570-bib-0025){ref-type="ref"}, [26](#jdv15570-bib-0026){ref-type="ref"}, [41](#jdv15570-bib-0041){ref-type="ref"}, [56](#jdv15570-bib-0056){ref-type="ref"}, [57](#jdv15570-bib-0057){ref-type="ref"}, [58](#jdv15570-bib-0058){ref-type="ref"}, [59](#jdv15570-bib-0059){ref-type="ref"}, [60](#jdv15570-bib-0060){ref-type="ref"}, [61](#jdv15570-bib-0061){ref-type="ref"}, [62](#jdv15570-bib-0062){ref-type="ref"}
  Imiquimod 3.75%                                           Immunomodulator: stimulates interferon and cytokine production                                           Once daily before bedtime for up to 8 weeks                                                                       19--37               15--19                EfficacyShort treatment durationSimple regimenEasy self‐applicationInflammatory reactions extending beyond treatment area can show the infected area                                               Inflammatory reactions extending beyond treatment areaResponse may be slow                                                                                                         [20](#jdv15570-bib-0020){ref-type="ref"}, [27](#jdv15570-bib-0027){ref-type="ref"}, [28](#jdv15570-bib-0028){ref-type="ref"}, [29](#jdv15570-bib-0029){ref-type="ref"}
  Sinecatechins 10% and 15%                                 Inflammatory response modulator                                                                          Three times daily for up to 16 weeks                                                                              40--81%              7--12                 EfficacySelf‐applicationLower recurrence rates than ablative techniques                                                                                                                            Intense application site reactionsLower clearance rates than ablative techniquesRepeat 3 times daily administration may affect adherenceNeed for sanitary pads                     [20](#jdv15570-bib-0020){ref-type="ref"}, [30](#jdv15570-bib-0030){ref-type="ref"}, [31](#jdv15570-bib-0031){ref-type="ref"}, [32](#jdv15570-bib-0032){ref-type="ref"}, [33](#jdv15570-bib-0033){ref-type="ref"}, [34](#jdv15570-bib-0034){ref-type="ref"}
  **Other topical therapy**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Podophyllotoxin 0.5% (alcoholic solution) 0.15% (cream)   Antimitotic agent induces tissue necrosis                                                                Twice‐daily to affected areas for 3 consecutive days per week; discontinue for 4 days; repeat for up to 4 weeks   45--94               11--100               EfficacyEasy self‐application                                                                                                                                                                      High recurrence rateComplicated regimenIntense application site reactions                                                                                                          [20](#jdv15570-bib-0020){ref-type="ref"}, [31](#jdv15570-bib-0031){ref-type="ref"}, [35](#jdv15570-bib-0035){ref-type="ref"}, [36](#jdv15570-bib-0036){ref-type="ref"}, [37](#jdv15570-bib-0037){ref-type="ref"}, [38](#jdv15570-bib-0038){ref-type="ref"}, [39](#jdv15570-bib-0039){ref-type="ref"}, [40](#jdv15570-bib-0040){ref-type="ref"}, [42](#jdv15570-bib-0042){ref-type="ref"}, [43](#jdv15570-bib-0043){ref-type="ref"}, [44](#jdv15570-bib-0044){ref-type="ref"}, [63](#jdv15570-bib-0063){ref-type="ref"}
  Nitric--zinc complex topical solution                     Induces a caustic effect on the wart through mummification and protein denaturation/coagulation action   Once or up to four times; repeat at 2‐week intervals if needed                                                    90--99               Not evaluated         EfficacyEasy application                                                                                                                                                                           Current evidence in AGW available from a limited number of patients onlyInvestigation of recurrence rate is required                                                               [64](#jdv15570-bib-0064){ref-type="ref"}

AGW, anogenital warts.
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Ablative techniques {#jdv15570-sec-0010}
-------------------

Ablative techniques are commonly used by physicians to remove warts in daily practice. However, most are awkward and painful for the patient. The major frustration is the high rate of recurrence with these treatments (see below) and the need for repeat therapeutic interventions. Ablative techniques are associated with a risk of bleeding, tissue destruction, slow wound healing and scarring.[44](#jdv15570-bib-0044){ref-type="ref"}, [66](#jdv15570-bib-0066){ref-type="ref"}

### Cryotherapy {#jdv15570-sec-0011}

Cryotherapy is the freezing of AGW using liquid nitrogen and is often used at a patient\'s first clinic visit to help initiate removal of the AGW. Various handheld devices, such as Hydrozid^®^ (Dunelm Pharmaceuticals, Drogheda, Ireland), as well as cryotherapy machines can be used for the procedure. Hydrozid^®^ is a disposable canister, which can be sprayed accurately onto the wart (Fig. [3](#jdv15570-fig-0003){ref-type="fig"}). This treatment option can be repeated weekly, biweekly or every 3 weeks and is a relatively simple, inexpensive technique, requiring minimal training. However, it requires many clinic visits and a second or third cycle of freezing may be needed. Clearance rates of 46--96% have been reported although treatment can cause pain, necrosis and blistering.[45](#jdv15570-bib-0045){ref-type="ref"}, [46](#jdv15570-bib-0046){ref-type="ref"}, [47](#jdv15570-bib-0047){ref-type="ref"}, [48](#jdv15570-bib-0048){ref-type="ref"}, [49](#jdv15570-bib-0049){ref-type="ref"}, [66](#jdv15570-bib-0066){ref-type="ref"} For non‐Caucasians, post‐inflammatory hypo/hyperpigmentation after treatment with cryotherapy can be frustrating; therefore, this should be discussed with patients before proceeding with this treatment option.

![Clearance of anogenital warts with Hydrozid^®^ cryotherapy: (a) wart on prepuce; (b) hole selected from template to shield surrounding tissue; (c) wart sprayed for a few seconds until frozen.](JDV-33-1006-g003){#jdv15570-fig-0003}

### Carbon dioxide and Nd:YAG laser {#jdv15570-sec-0012}

Carbon dioxide (CO~2~) and Nd:YAG lasers vaporize lesions using focused infrared light energy; however, it is not always possible to know the extent of the infected tissue, and therefore, vaporizing large regions around the warts is not always feasible. Local anaesthesia is usually required, especially on extensive and thick lesions as it can penetrate deeply into the lesions.[50](#jdv15570-bib-0050){ref-type="ref"}

This treatment option is used less frequently than other therapies as it requires specialized and costly equipment, and has an increased risk of serious complications unless used by an experienced physician.[1](#jdv15570-bib-0001){ref-type="ref"} However, clearance rates of up to 95% have been reported in clinical studies, with a head‐to‐head comparison showing greater efficacy than cryotherapy.[47](#jdv15570-bib-0047){ref-type="ref"}, [48](#jdv15570-bib-0048){ref-type="ref"}, [50](#jdv15570-bib-0050){ref-type="ref"} It is important to note that fumes from laser treatment contain contagious particles and adequate measures should be taken to prevent the virus from spreading. Masks and smoke evacuators should therefore be used.

### Electrocautery {#jdv15570-sec-0013}

Electrocautery uses high‐frequency electrical currents to destroy AGW and requires local anaesthesia and physician expertise.[18](#jdv15570-bib-0018){ref-type="ref"}, [20](#jdv15570-bib-0020){ref-type="ref"} Clinical studies have shown clearance rates of 35--94%.[20](#jdv15570-bib-0020){ref-type="ref"}, [49](#jdv15570-bib-0049){ref-type="ref"}, [51](#jdv15570-bib-0051){ref-type="ref"} As fumes from electrocautery contain contagious particles, preventative measures should be put in place to stop the virus spreading.

### Surgery {#jdv15570-sec-0014}

Surgery is performed using scissors or a scalpel and is particularly suited for removing large lesions causing obstruction. Local or general anaesthesia is required, and patients may experience post‐operative pain.[50](#jdv15570-bib-0050){ref-type="ref"} Clearance rates of up to 93% have been reported in clinical studies.[51](#jdv15570-bib-0051){ref-type="ref"}, [52](#jdv15570-bib-0052){ref-type="ref"}, [53](#jdv15570-bib-0053){ref-type="ref"}

### Trichloroacetic acid (TCA; 33--50%) {#jdv15570-sec-0015}

Physician‐applied acidic treatment causes a chemical burn that destroys the AGW. The acid can be administered up to three times per week until the warts have cleared. This process requires a skilled professional to choose the appropriate lesion and duration of application but it is easy to apply and effective for treating AGW, with clearance rates of 70--100% reported in clinical studies (Fig. [4](#jdv15570-fig-0004){ref-type="fig"}). However, side‐effects such as local discomfort, burning and ulceration are common, hence the need for careful application.[45](#jdv15570-bib-0045){ref-type="ref"}, [46](#jdv15570-bib-0046){ref-type="ref"}, [47](#jdv15570-bib-0047){ref-type="ref"}, [53](#jdv15570-bib-0053){ref-type="ref"}, [55](#jdv15570-bib-0055){ref-type="ref"}, [66](#jdv15570-bib-0066){ref-type="ref"} TCA can also be used to treat small lesions; however, it is not frequently used due to a high recurrence rate and the risk of side‐effects.

![Clearance of anogenital warts with trichloroacetic acid: (a) application with a double‐ended cotton bud to allow any trickles to be instantly dried up; (b) rapid occurrence of frosting after application; (c) months later, no sign of warts and only slight scarring.](JDV-33-1006-g004){#jdv15570-fig-0004}

Immunotherapies {#jdv15570-sec-0016}
---------------

Immunotherapies use stimulation of the body\'s own immune system to clear infected lesions.

### Imiquimod 5% or 3.75% {#jdv15570-sec-0017}

Imiquimod is an immune response modifier with antiviral activity. This Toll‐like receptor 7 agonist induces the production of cytokines, which enhance the ability of antigen presenting cells to present viral antigens to reactive T lymphocytes.[21](#jdv15570-bib-0021){ref-type="ref"}, [22](#jdv15570-bib-0022){ref-type="ref"}, [65](#jdv15570-bib-0065){ref-type="ref"} Imiquimod 5% has been approved for the treatment of AGW worldwide, whereas imiquimod 3.75% is only approved in certain countries such as the United States of America (USA) and Canada. Imiquimod 5% is self‐applied by the patient three nights per week for up to 16 weeks; if no improvement has occurred after 4--6 weeks, treatment can be applied daily. In comparison, imiquimod 3.75% is self‐applied once‐nightly for up to 8 weeks. Imiquimod 5% may be applied for longer durations if there is a good clinical result but complete clearance has not occurred at the end of the initial treatment period.[28](#jdv15570-bib-0028){ref-type="ref"} Both imiquimod formulations are associated with local skin reactions such as erythema, pruritus, burning, pain and sometimes erosions. These are all signs that the immune system has been activated. The lower concentration of imiquimod in the 3.75% cream is associated with improved tolerability. In addition, the shorter treatment duration and dosing simplicity may improve patients' adherence to the regimen.[27](#jdv15570-bib-0027){ref-type="ref"} AGW clearance rates from clinical studies range from 35 to 75% with the 5% cream[20](#jdv15570-bib-0020){ref-type="ref"}, [23](#jdv15570-bib-0023){ref-type="ref"}, [24](#jdv15570-bib-0024){ref-type="ref"}, [41](#jdv15570-bib-0041){ref-type="ref"}, [56](#jdv15570-bib-0056){ref-type="ref"}, [57](#jdv15570-bib-0057){ref-type="ref"}, [58](#jdv15570-bib-0058){ref-type="ref"}, [59](#jdv15570-bib-0059){ref-type="ref"}, [60](#jdv15570-bib-0060){ref-type="ref"}, [61](#jdv15570-bib-0061){ref-type="ref"}, [62](#jdv15570-bib-0062){ref-type="ref"} and 19 to 37% with the 3.75% formulation,[20](#jdv15570-bib-0020){ref-type="ref"}, [27](#jdv15570-bib-0027){ref-type="ref"}, [28](#jdv15570-bib-0028){ref-type="ref"}, [29](#jdv15570-bib-0029){ref-type="ref"} with higher clearance rates in women than men.[29](#jdv15570-bib-0029){ref-type="ref"} Further studies have shown that patients find imiquimod 5% to be both acceptable and preferable to other AGW treatments. A study of 559 patients with AGW reported excellent, very good or good with imiquimod 5% in 27.4%, 36.1% and 23.0% of patients, respectively.[25](#jdv15570-bib-0025){ref-type="ref"} In addition, a survey of 629 patients showed that imiquimod 5% was rated better in terms of overall satisfaction, convenience, time to clearance and lack of associated pain than other AGW therapies.[26](#jdv15570-bib-0026){ref-type="ref"}

### Sinecatechins {#jdv15570-sec-0018}

Sinecatechins consist of green tea polyphenols, which have anti‐inflammatory, anti‐proliferative, pro‐apoptotic and antiviral properties, although their exact mode of action is unknown.[30](#jdv15570-bib-0030){ref-type="ref"}, [31](#jdv15570-bib-0031){ref-type="ref"} They are available for the treatment of AGW as a 10% and 15% ointment or cream, which is self‐applied by the patient three times per day for a maximum of 16 weeks.[31](#jdv15570-bib-0031){ref-type="ref"} In comparison, imiquimod 5% is applied three times weekly while application of imiquimod 3.75% is once daily.[30](#jdv15570-bib-0030){ref-type="ref"} Patient adherence to dosing regimens should be considered, as compliance is important in achieving treatment effectiveness.[30](#jdv15570-bib-0030){ref-type="ref"} An additional factor that may affect compliance is that sinecatechin 15% ointment is a brown formulation,[67](#jdv15570-bib-0067){ref-type="ref"} which could stain light‐coloured clothing and bedding, reducing patient adherence.

Clinical studies of sinecatechins have shown similar clearance rates to that of imiquimod 5% therapy. Sinecatechins have resulted in complete clearance rates of 40--81%, with comparable differences in response rates between the 10% and 15% ointments.[31](#jdv15570-bib-0031){ref-type="ref"}, [32](#jdv15570-bib-0032){ref-type="ref"}, [33](#jdv15570-bib-0033){ref-type="ref"}, [34](#jdv15570-bib-0034){ref-type="ref"} Furthermore, the recurrence rate with sinecatechin 10% ointment was 6.8% after 12 weeks of treatment[68](#jdv15570-bib-0068){ref-type="ref"} and 12% with sinecatechin 10% cream following 12 weeks of treatment.[32](#jdv15570-bib-0032){ref-type="ref"} This was higher than the recurrence rate of 6.2% observed with imiquimod 5% treatment after 3 months and 6.3% at 6 months.[62](#jdv15570-bib-0062){ref-type="ref"} No significant difference in clearance or recurrence rates has been found between sinecatechin 10% cream and placebo.[30](#jdv15570-bib-0030){ref-type="ref"} No long‐term data are available for sinecatechins. The most commonly observed application site reactions are erythema, pruritus, irritation, pain and ulceration; these side‐effects may indicate the greater likelihood of a clinical response.[30](#jdv15570-bib-0030){ref-type="ref"}

Other topical therapies {#jdv15570-sec-0019}
-----------------------

### Podophyllotoxin 0.15% cream or 0.5% alcoholic solution {#jdv15570-sec-0020}

Podophyllotoxin stops division of infected cells causing tissue necrosis.[20](#jdv15570-bib-0020){ref-type="ref"}, [31](#jdv15570-bib-0031){ref-type="ref"}, [35](#jdv15570-bib-0035){ref-type="ref"} It can be self‐applied by patients twice‐daily for three consecutive days, separated by a 4‐day treatment‐free period and repeated for up to 4 weeks. Patients need to carefully apply the solution to the lesions and avoid contact with healthy skin. Clearance rates from clinical studies range from 45 to 94%, with common side‐effects including pain, itching, burning, erosion and inflammation.[20](#jdv15570-bib-0020){ref-type="ref"}, [31](#jdv15570-bib-0031){ref-type="ref"}, [35](#jdv15570-bib-0035){ref-type="ref"}, [36](#jdv15570-bib-0036){ref-type="ref"}, [37](#jdv15570-bib-0037){ref-type="ref"}, [38](#jdv15570-bib-0038){ref-type="ref"}, [39](#jdv15570-bib-0039){ref-type="ref"}, [40](#jdv15570-bib-0040){ref-type="ref"}, [42](#jdv15570-bib-0042){ref-type="ref"}, [43](#jdv15570-bib-0043){ref-type="ref"}, [44](#jdv15570-bib-0044){ref-type="ref"}, [63](#jdv15570-bib-0063){ref-type="ref"}

### Nitric zinc {#jdv15570-sec-0021}

Nitric--zinc complex is a solution for topical application containing nitric acid, zinc, copper and organic acids, currently used to treat common warts.[64](#jdv15570-bib-0064){ref-type="ref"} It has a caustic effect on the wart through mummification and protein denaturation or a coagulation action.[64](#jdv15570-bib-0064){ref-type="ref"} The solution can be applied topically once, or up to four times, at 2‐week intervals until a complete clinical cure rate is observed.[64](#jdv15570-bib-0064){ref-type="ref"} Clearance rates in one study ranged from 90 to 99%, and the product was well tolerated with no serious adverse events recorded.[64](#jdv15570-bib-0064){ref-type="ref"} Initial data suggest promising efficacy in AGW; however, additional studies are needed.

Guidance for preventing the recurrence of AGW {#jdv15570-sec-0022}
---------------------------------------------

Anogenital warts recurrence is common and frustrating for patients and physicians.[18](#jdv15570-bib-0018){ref-type="ref"} Recurrence rates with conventional ablative techniques are relatively high (Table [3](#jdv15570-tbl-0003){ref-type="table"}), since these methods only remove the visible wart without affecting the underlying HPV infection.[44](#jdv15570-bib-0044){ref-type="ref"}, [66](#jdv15570-bib-0066){ref-type="ref"} Of currently available treatments, recurrence rates are very low with immunotherapies, imiquimod (6--19%)[20](#jdv15570-bib-0020){ref-type="ref"}, [23](#jdv15570-bib-0023){ref-type="ref"}, [28](#jdv15570-bib-0028){ref-type="ref"}, [41](#jdv15570-bib-0041){ref-type="ref"}, [56](#jdv15570-bib-0056){ref-type="ref"}, [57](#jdv15570-bib-0057){ref-type="ref"}, [60](#jdv15570-bib-0060){ref-type="ref"}, [62](#jdv15570-bib-0062){ref-type="ref"} and sinecatechins (4--12%),[32](#jdv15570-bib-0032){ref-type="ref"}, [33](#jdv15570-bib-0033){ref-type="ref"}, [34](#jdv15570-bib-0034){ref-type="ref"} as these treatments stimulate the host\'s immune response to clear the warts.

Studies have shown that a combination of ablative techniques followed by immunotherapy may lead to even lower recurrence rates; ablation provides rapid clearance but has high recurrence rates while immunotherapy has slow clearance rates and a lower risk of recurrence.[20](#jdv15570-bib-0020){ref-type="ref"}, [69](#jdv15570-bib-0069){ref-type="ref"} A study of 211 patients showed that imiquimod 5% applied within 3 weeks after laser therapy (to ensure complete wound healing) was associated with a low rate of wart recurrences of 11.8% over 6 months of follow‐up.[69](#jdv15570-bib-0069){ref-type="ref"} Results of a 3‐arm, open‐label study involving 358 patients showed that 6‐month recurrence rates in those randomized to a combination of ablation followed by imiquimod 5% (8%) were lower than those after ablation alone (26%), but similar to imiquimod 5% monotherapy (6%).[62](#jdv15570-bib-0062){ref-type="ref"} Furthermore, the results of a retrospective case series of 27 patients showed that combined treatment with cryotherapy, podophyllin 25% and subsequent use of sinecatechins 15% ointment led to a recurrence rate of 7.4% after 6 months of follow‐up.[70](#jdv15570-bib-0070){ref-type="ref"} Gilson *et al*.,[71](#jdv15570-bib-0071){ref-type="ref"} further showed that a combination of cryotherapy and podophyllotoxin cream 0.15% resulted in a higher clearance rate (60%) than with cryotherapy alone (45.7%) at both 4 and 12 weeks. However, these differences were not statistically significant.[71](#jdv15570-bib-0071){ref-type="ref"}

Pre‐treatment of AGW with imiquimod to stimulate an immune reaction followed by surgery is also associated with low recurrence rates. A retrospective study of 60 patients with anogenital warts showed that the recurrence rate during long‐term follow‐up (up to 7 years) was lower for patients with complete responses to imiquimod 5% monotherapy (15%), or with surgical removal of residual warts after imiquimod 5% (20%), compared with surgery alone (65%).[54](#jdv15570-bib-0054){ref-type="ref"}

A simplified algorithm for AGW treatment {#jdv15570-sec-0023}
----------------------------------------

A new simplified treatment algorithm for AGW is shown in Fig. [5](#jdv15570-fig-0005){ref-type="fig"}. Patients with a confirmed clinical diagnosis of AGW are initially classified by their number of warts. Patients with 1--5 warts may be treated in the first instance with ablation. Once the lesions have healed, immunotherapy can be used for 2 months to treat remaining warts and/or prevent recurrence. The choice of ablative technique is at the discretion of the physician taking factors such as the location of the wart into consideration. For those with more than five warts, the expert\'s recommendation is to pre‐treat the AGW with an immunotherapy for 2 months to see whether an immune response can be stimulated. If the warts are still present following this treatment, an ablative technique can be used to remove the AGW. It is recommended to use a second 2‐month course of immunotherapy to treat remaining warts and/or prevent recurrence. It is recognized that there are many different algorithms for the treatment of AGW and that the choice is dependent on many factors. For example, if all staff are experienced in ablative techniques, then irrespective of the number of warts, the clinic protocol may dictate that ablation is used on all patients with warts at first visit, followed by immunotherapy. In the UK, this is usual practice as it is preferable for a reduced number of clinic visits.

![A new simplified algorithm for the treatment of anogenital warts. \*If large warts (too large for local TCA or cryotherapy), see Fig. [6](#jdv15570-fig-0006){ref-type="fig"}; \*\*Even if some keratinized lesions are present, the goal is to treat the entire area so that non‐keratinized lesions are treated with immunotherapy followed by removal of keratinized lesions by ablative techniques. PCR, polymerase chain reaction; TCA, trichloroacetic acid](JDV-33-1006-g005){#jdv15570-fig-0005}

An algorithm for the treatment of patients with large AGW is also shown in Fig. [6](#jdv15570-fig-0006){ref-type="fig"}. Large warts are defined as too large for local TCA or cryotherapy, and patients with these warts should be referred to a specialist. Based on clinical experience, our recommendation is to initially pre‐treat the AGW with immunotherapy for up to 16 weeks to stimulate an immune reaction to reduce the risk of recurrence. In support of this, long‐term recurrence rates are lower for patients pre‐treated with imiquimod 5% followed by surgery compared with surgery alone.[54](#jdv15570-bib-0054){ref-type="ref"}, [70](#jdv15570-bib-0070){ref-type="ref"} Evidence for other immunotherapies in this setting is not currently available. The AGW should then be surgically removed under general anaesthesia, with immunotherapy being re‐started if there are residual or recurrent lesions. A histological examination of the excised tissue should be performed to exclude verrucous or squamous cell carcinoma. An example of a patient treated with this approach is shown in Fig. [7](#jdv15570-fig-0007){ref-type="fig"}.

![A new simplified algorithm for the treatment of large anogenital warts. \*Large warts are defined as too large for local trichloroacetic acid or cryotherapy.](JDV-33-1006-g006){#jdv15570-fig-0006}

![Example patient with large anogenital warts pre‐treated with imiquimod before surgery: (a) vulval and anal warts in a 19‐year old who was pre‐treated with imiquimod for 2 months while surgery was organized; (b) needle diathermy with smoke extractor at the start of surgery; (b) 3 weeks post‐operation, the patient remained clear of warts 9 months later.](JDV-33-1006-g007){#jdv15570-fig-0007}

Guidance for daily practice situations {#jdv15570-sec-0024}
--------------------------------------

Guidance for daily practice situations and the subsequent action that can be taken are shown in Table [4](#jdv15570-tbl-0004){ref-type="table"}.[3](#jdv15570-bib-0003){ref-type="ref"}, [8](#jdv15570-bib-0008){ref-type="ref"}, [12](#jdv15570-bib-0012){ref-type="ref"}, [16](#jdv15570-bib-0016){ref-type="ref"}, [23](#jdv15570-bib-0023){ref-type="ref"}, [26](#jdv15570-bib-0026){ref-type="ref"}, [30](#jdv15570-bib-0030){ref-type="ref"}, [50](#jdv15570-bib-0050){ref-type="ref"}, [54](#jdv15570-bib-0054){ref-type="ref"}, [56](#jdv15570-bib-0056){ref-type="ref"}, [62](#jdv15570-bib-0062){ref-type="ref"}, [66](#jdv15570-bib-0066){ref-type="ref"}, [72](#jdv15570-bib-0072){ref-type="ref"}, [73](#jdv15570-bib-0073){ref-type="ref"}, [74](#jdv15570-bib-0074){ref-type="ref"}, [75](#jdv15570-bib-0075){ref-type="ref"}, [76](#jdv15570-bib-0076){ref-type="ref"}, [77](#jdv15570-bib-0077){ref-type="ref"}, [78](#jdv15570-bib-0078){ref-type="ref"}, [79](#jdv15570-bib-0079){ref-type="ref"}, [80](#jdv15570-bib-0080){ref-type="ref"}

###### 

Guidance for daily practice situations and the subsequent action that can be taken

  Daily practice situations                                        Actions
  ---------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **AGW remaining following ablation**                             Explain that residual or recurrent warts post‐ablation indicate that the immune system has not been activated, which can be more frequent in primary infectionsInitiate immunotherapy
  **Experience or fear of local side‐effects in genital area**     Explain how immunotherapy worksAdvise patients that local side‐effects are a sign that the immune system has been activated and the therapy is working[26](#jdv15570-bib-0026){ref-type="ref"}, [30](#jdv15570-bib-0030){ref-type="ref"}, [54](#jdv15570-bib-0054){ref-type="ref"}, [66](#jdv15570-bib-0066){ref-type="ref"}, [79](#jdv15570-bib-0079){ref-type="ref"}With imiquimod, explain that skin reactions are common and can sometimes be associated with adverse events (headache, fatigue, myalgia and nausea). Frequency of application may be reduced or treatment can be temporarily stopped if necessary[79](#jdv15570-bib-0079){ref-type="ref"}
  **Limited initial efficacy with imiquimod**                      Explain that some patients' immune systems are slow to activate[23](#jdv15570-bib-0023){ref-type="ref"}, [56](#jdv15570-bib-0056){ref-type="ref"}Use an ablative method which can debulk and allow easier penetrationReassure and continue with imiquimodInform the patient that some patients need the full 16‐week treatment course or even longer
  **Lack of adherence**                                            Determine the extent to which the patient has adhered to the treatment regimenUnderstand the reasons for lack of adherence (e.g., complicated regimen/side‐effects) and ensure the patient is provided with sufficient information about AGW and the different treatments that is clear and simple, both verbally and in written form[8](#jdv15570-bib-0008){ref-type="ref"}, [75](#jdv15570-bib-0075){ref-type="ref"}, [79](#jdv15570-bib-0079){ref-type="ref"}Try an alternative therapy that is associated with better adherence/improved patient satisfaction[26](#jdv15570-bib-0026){ref-type="ref"}
  **Lumps left may not be true warts**                             Explain (with the help of images; Fig. [2](#jdv15570-fig-0002){ref-type="fig"}) that lumps left after treatment may not be genital warts and that they could be large, normal glands.
  **Heavy cigarette smoking**                                      Explain that smoking depresses the immune system, particularly in relation to viruses[74](#jdv15570-bib-0074){ref-type="ref"} and it is well recognized that smokers have more difficulty clearing warts and are more likely to get recurrences.[16](#jdv15570-bib-0016){ref-type="ref"} Smoking cessation should be encouraged
  **Pregnancy**                                                    Explain that pregnancy is an immune suppressed state and therefore wart infections can become large during pregnancy but will usually disappear within weeks of delivery[76](#jdv15570-bib-0076){ref-type="ref"}During pregnancy, the warts should not be treated if they do not represent an obstacle to delivery. If needed, only use ablative methods, e.g., cryotherapy or trichloroacetic acid[3](#jdv15570-bib-0003){ref-type="ref"}, [12](#jdv15570-bib-0012){ref-type="ref"}, [50](#jdv15570-bib-0050){ref-type="ref"}Avoid extensive laser vaporization, electrocautery or surgery during the 6--8 weeks before deliveryBe aware that in rare cases, HPV can be transmitted during child birth resulting in recurrent respiratory papillomatosis in the infant[73](#jdv15570-bib-0073){ref-type="ref"}, [78](#jdv15570-bib-0078){ref-type="ref"}
  **Immune suppression**                                           Establish the patient\'s HIV statusCheck to see whether they are on immunosuppressive drugs for inflammatory bowel disease, rheumatoid arthritis etc. Reassure the patient that clearance will still be achieved but it may take longer
  **Other conditions (i.e. diabetes, eczema, psoriasis)**          Determine if the patient has other conditions, such as diabetes, which are associated with more extensive AGW and recurrences that may require prolonged treatment[80](#jdv15570-bib-0080){ref-type="ref"}More ablation and prolonged imiquimod courses may be requiredIt is recommended not to use imiquimod if there is eczema, psoriasis or other dermatoses in the genital area[77](#jdv15570-bib-0077){ref-type="ref"}
  **Concomitant local infections (e.g. bacterial, fungal etc.)**   Should be treated promptly at any stage of AGW therapy
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Preventing AGW {#jdv15570-sec-0025}
--------------

Anogenital warts can now be effectively prevented using the quadrivalent (HPV 6, 11, 16 and 18) or nanovalent (HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58) HPV vaccines; these protect against HPV types that cause AGW, cervical cancer and other types of anogenital and oral cancer. The HPV quadrivalent vaccine has shown to be up to 100% effective in preventing AGW in association with vaccine‐type HPV in women.[81](#jdv15570-bib-0081){ref-type="ref"}, [82](#jdv15570-bib-0082){ref-type="ref"} After its introduction in Australia, a study with a 4‐year follow‐up showed a 59% reduction in the prevalence of AGW in young females.[83](#jdv15570-bib-0083){ref-type="ref"} There was also a concomitant, although less marked, decline in AGW in heterosexual men following introduction of the vaccine.[83](#jdv15570-bib-0083){ref-type="ref"}, [84](#jdv15570-bib-0084){ref-type="ref"} Prevention of AGW with the HPV vaccine could therefore result in substantial savings in healthcare costs and reduction in workload for sexual health clinics.[85](#jdv15570-bib-0085){ref-type="ref"} The vaccine is also effective in 12‐ to 15‐year‐old boys and is licensed for use in both sexes in most countries where it is available.[85](#jdv15570-bib-0085){ref-type="ref"}, [86](#jdv15570-bib-0086){ref-type="ref"} Evidence on whether the vaccination could be useful in AGW treatment is not yet clear; however, there are scientific data supporting use of the vaccination in individuals previously exposed to HPV.[87](#jdv15570-bib-0087){ref-type="ref"}

Conclusions {#jdv15570-sec-0026}
===========

The guidance provided will help physicians with the diagnosis and management of AGW in daily clinical practice, in order to improve the health and quality of life of patients with AGW. The suggested therapeutic approach is flexible, allowing physicians to choose treatment depending on local availability and physician expertise, as well as considering patient preferences.
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